Extended indication Advanced systemic mastocytosis (AdvSM). AYVAKYT is indicated as monotherapy for the treatment of
Therapeutic value No estimate possible yet
Total cost 13,502,791.75
Registration phase Registered

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information